CEACAM-7: A predictive marker for rectal cancer recurrence

Surgery

Volumn 147, Issue 5, 2010, Pages 713-719

  Messick, Craig A ^a   Sanchez, Julian ^a   DeJulius, Kathryn L ^a   Hammel, Jeffrey ^a   Ishwaran, Hemant ^a   Kalady, Matthew F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CEACAM 7; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVOR; CANCER TISSUE; COMPARATIVE STUDY; DATA BASE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; FROZEN SECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CANCER; RECTUM MUCOSA; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CELL ADHESION MOLECULES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL MUCOSA; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MORBIDITY; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; RNA, MESSENGER; TISSUE BANKS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950857698     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.10.056     Document Type: Article

References (24)

1. Walker J., and Quirke P. Prognosis and response to therapy in colorectal cancer. Eur J Cancer 38 (2002) 880-886
2. You Y.N., Baxter N.N., Stewart A., and Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified? A nationwide cohort study from the National Cancer Database. Ann Surg 245 (2007) 726-733
3. Macdonald J.S. Adjuvant therapy for colon cancer. CA Cancer J Clin 47 (1997) 243-256
4. Scholzel S., Zimmermann W., Schwarzkopf G., Grunert F., Rogaczewski B., and Thompson J. Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol 156 (2000) 595-605
5. Thompson J., Seitz M., Chastre E., Ditter M., Aldrian C., Gespach C., et al. Down-regulation of carcinoembryonic antigen family member 2 expression is an early event in colorectal tumorigenesis. Cancer Res 57 (1997) 1776-1784
6. Hashino J., Fukuda Y., Oikawa S., Nakazato H., and Nakanishi T. Metastatic potential of human colorectal carcinoma SW1222 cells transfected with cDNA encoding carcinoembryonic antigen. Clin Exp Metastasis 12 (1994) 324-328
7. Pretlow T.P., Roukhadze E.V., O'Riordan M.A., Chan J.C., Amini S.B., and Stellato T.A. Carcinoembryonic antigen in human colonic aberrant crypt foci. Gastroenterology 107 (1994) 1719-1725
8. Thompson J., Zimmermann W., Nollau P., Neumaier M., Weber-Arden J., Schrewe H., et al. CGM2, a member of the carcinoembryonic antigen gene family is down-regulated in colorectal carcinomas. J Biol Chem 30 269 (1994) 32924-32931
9. Heid C.A., Stevens J., Livak K.J., and Williams P.M. Real time quantitative PCR. Genome Res 6 (1996 Oct) 986-994
10. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
11. Jantscheff P., Terracciano L., Lowy A., Glatz-Krieger K., Grunert F., Micheel B., et al. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol 21 (2003) 3638-3646
12. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
13. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
14. O'Neil B.H., and Tepper J.E. Current options for the management of rectal cancer. Curr Treat Options Oncol 8 (2007) 331-338
15. Lavery I.C., Lopez-Kostner F., Fazio V.W., Fernandez-Martin M., Milsom J.W., and Church J.M. Chances of cure are not compromised with sphincter-saving procedures for cancer of the lower third of the rectum. Surgery 122 (1997) 779-785
16. Robbins D.H., and Itzkowitz S.H. The molecular and genetic basis of colon cancer. Med Clin North Am 86 (2002) 1467-1495
17. Russo A., Bazan V., Iacopetta B., Kerr D., Soussi T., and Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23 (2005) 7518-7528
18. Deng G., Bell I., Crawley S., Gum J., Terdiman J.P., Allen B.A., et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10 (2004) 191-195
19. Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
20. Douard R., Wind P., Sales J.P., Landi B., Berger A., Benichou J., et al. Long-term prognostic value of detection of circulating colorectal cancer cells using CGM2 reverse transcriptase-polymerase chain reaction assay. Surgery 139 (2006) 556-562
21. Aranda-Anzaldo A. Cancer development and progression: a non-adaptive process driven by genetic drift. Acta Biotheor 49 (2001) 89-108
22. Scheel C., Onder T., Karnoub A., and Weinberg R.A. Adaptation versus selection: the origins of metastatic behavior. Cancer Res 67 (2007) 11476-11480
23. Paschos K.A., Canovas D., and Bird N.C. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 21 (2009) 665-674
24. Graff J.R., Gabrielson E., Fujii H., Baylin S.B., and Herman J.G. Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275 (2000) 2727-2732